Details for Patent: 9,512,165
✉ Email this page to a colleague
Which drugs does patent 9,512,165 protect, and when does it expire?
Patent 9,512,165 protects ZURZUVAE and is included in one NDA.
This patent has seventy-nine patent family members in twenty-seven countries.
Summary for Patent: 9,512,165
| Title: | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| Abstract: | Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus. |
| Inventor(s): | Gabriel MARTINEZ BOTELLA, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis |
| Assignee: | Sage Therapeutics Inc |
| Application Number: | US14/785,171 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 9,512,165
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-001 | Oct 31, 2023 | RX | Yes | No | 9,512,165 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Biogen | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-002 | Oct 31, 2023 | RX | Yes | No | 9,512,165 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Biogen | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-003 | Oct 31, 2023 | RX | Yes | Yes | 9,512,165 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,512,165
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2986623 | ⤷ Start Trial | C20260008 | Finland | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | CA 2026 00010 | Denmark | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | 301371 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | PA2026511 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | 2026C/704 | Belgium | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | LUC50042 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2986623 | ⤷ Start Trial | 202640008 | Slovenia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
